Immusoft Corp

Seattle, WA

UEI
N6KEM57XYJB7
CAGE
5X7L8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
454 N 34th St #100, Seattle, WA 98103, USA
Website
immusoft.com
Founded
2009
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Transposon engineered b cell therapy for hunter syndrome R43NS120264 National Institute of Neurological Disorders and Stroke (NIH) $466,804
Sleeping beauty engineered b cells for mucopolysaccharidosis R44GM115192 National Institute of General Medical Sciences (NIH) $3,589,215
Testing of novel system to deliver VRC01 in mouse model R41AI098603 National Institutes of Health $300,000

Quick answers

Is Immusoft Corp registered in SAM.gov?

Yes. Immusoft Corp's SAM.gov registration is active through January 16, 2027.

What is Immusoft Corp's most recent federal award?

Immusoft Corp's most recent federal grant award is Transposon engineered b cell therapy for hunter syndrome (R43NS120264), from National Institute of Neurological Disorders and Stroke (NIH), on September 30, 2020.

On GovTribe

See Immusoft Corp's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login